RENCA Syngeneic Model Overview
The RENCA syngeneic model is a murine renal cell carcinoma (RCC) system derived from BALB/c mice. It is one of the most widely used preclinical models for kidney cancer and has been instrumental in understanding tumor–immune interactions, metastasis, and therapeutic response. RENCA tumors are highly vascularized, immunogenic, and capable of forming both primary and metastatic lesions, closely resembling the biological behavior of clear cell renal cell carcinoma in humans.
When implanted subcutaneously, intravenously, or orthotopically into the kidney, RENCA cells produce consistent tumor growth and can generate spontaneous lung metastases depending on the implantation route. The model’s immunocompetent background and reliable metastatic potential make it valuable for testing immunotherapy, anti-angiogenic agents, and combination treatment strategies in renal cancer research.
Request a Custom Quote for RENCA Syngeneic ModelBiological and Molecular Characteristics
The RENCA cell line was established from a spontaneous renal cortical adenocarcinoma in a BALB/c mouse and retains epithelial morphology with high proliferative potential. These cells express typical markers of renal carcinoma, including carbonic anhydrase IX (CAIX), cytokeratin, and vimentin, and exhibit constitutive activation of pro-angiogenic and immunomodulatory pathways. RENCA tumors are rich in vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), and transforming growth factor-beta (TGF-beta), contributing to angiogenesis and immune evasion.
The tumor microenvironment is characterized by abundant macrophages and myeloid-derived suppressor cells (MDSCs), along with infiltrating T lymphocytes that display signs of exhaustion. This immune composition makes the RENCA system particularly relevant for testing checkpoint inhibitors, cytokine therapies, and drugs targeting the tumor vasculature. The model’s robust growth and reproducibility make it one of the standard tools in translational renal oncology.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Spontaneous renal cortical adenocarcinoma (mouse) |
| Histological type | Clear cell renal cell carcinoma–like adenocarcinoma |
| Inoculation route | Subcutaneous, orthotopic (renal capsule), or intravenous |
| Tumor take rate | >90% |
| Doubling time | Approximately 3–5 days in vivo |
| Metastatic potential | Moderate to high; lung metastases common via IV or orthotopic routes |
| Immunophenotype | Moderately immunogenic; macrophage and T-cell infiltration |
| Common applications | Immunotherapy, angiogenesis inhibition, metastasis research, cytokine studies |
In Vivo Model Development and Tumorigenicity
RENCA tumors can be established through several implantation methods, depending on the study objective. Subcutaneous implantation in BALB/c mice produces solid, easily measurable tumors suitable for efficacy and mechanistic studies. Orthotopic implantation under the renal capsule generates tumors that mimic the anatomical and vascular characteristics of human renal cell carcinoma, including spontaneous metastasis to the lungs. Intravenous inoculation produces disseminated pulmonary metastases for evaluating systemic therapy efficacy.
Tumor development occurs rapidly, with visible subcutaneous tumors forming within 5–7 days and orthotopic tumors establishing measurable disease within two weeks. The RENCA model’s flexibility across implantation routes allows researchers to examine local tumor progression, immune infiltration, and metastatic dissemination in a physiologically relevant context. It remains a mainstay for studying immune checkpoint inhibitors, cytokine therapy, and vascular-targeted agents in renal cancer.
Request a Custom Quote for RENCA Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological examination of RENCA tumors reveals solid nests and glandular structures composed of polygonal epithelial cells with eosinophilic cytoplasm and vesicular nuclei. The tumors are highly vascularized and contain regions of hemorrhage, necrosis, and stromal fibrosis. In the orthotopic model, RENCA tumors invade adjacent renal tissue and blood vessels, resembling locally advanced human RCC.
Immunohistochemical staining confirms expression of cytokeratin, vimentin, and CAIX, verifying epithelial and renal differentiation. Ki-67 staining demonstrates high proliferative activity, while CD31 and VEGF staining indicate extensive neovascularization. Immune profiling shows infiltration by CD3-positive T cells and F4/80-positive macrophages, with moderate PD-L1 expression on both tumor and stromal cells. These features collectively reflect the immunogenic yet immune-modulated nature of renal cell carcinoma, making RENCA a robust and translationally relevant model for preclinical oncology.
Preclinical Applications and Drug Response
The RENCA syngeneic model has been extensively used to evaluate immunotherapeutic, targeted, and anti-angiogenic agents. It responds variably to PD-1 and CTLA-4 checkpoint blockade and demonstrates improved outcomes when treated with combination regimens involving cytokines, tyrosine kinase inhibitors, or VEGF-pathway antagonists. Studies have shown that IFN-alpha, IL-2, and GM-CSF enhance immune infiltration and synergize with checkpoint inhibitors to promote tumor regression.
The model is also widely applied in preclinical testing of anti-angiogenic therapies such as sunitinib and sorafenib, as well as in studies of metastatic spread and immune cell trafficking. Its ability to generate spontaneous metastases provides a valuable platform for studying the immune microenvironment in both primary and secondary tumor sites. Owing to its reproducibility and strong translational relevance, RENCA remains the gold-standard syngeneic model for renal cancer immunotherapy and angiogenesis research.
Request This Model
To request the RENCA syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for RENCA Syngeneic Model